FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer By Ogkologos - January 29, 2026 48 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRITON3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency MOST POPULAR Reflections on My First Year as NCI Director November 1, 2018 Pregnancy is Safe After Early Breast Cancer in Young Women with... July 17, 2020 Targeted Drug Trio Improves Survival in Colorectal Cancer with BRAF Mutations November 13, 2019 A new IARC live webinar on evidence in primary cancer prevention November 11, 2021 Load more HOT NEWS Julia Louis-Dreyfus Talks About The Side Effects of Chemotherapy Cancer, COVID-19, and Competing Threats to Indigenous Health Study Aims to Reduce Lung Cancer Stigma by Teaching Health Professionals... Firefighter Advocates For Men’s Health While He Battles Breast Cancer In...
